Lack of cardiac benefit after intramyocardial or intravenous injection of mesenchymal stem cell-derived extracellular vesicles supports the need for optimized cardiac delivery

Abstract

Aim: To determine the differences in improvement in cardiac function by intramyocardial (IM) vs. intravenous (IV) injection of human bone mesenchymal stem cell-derived extracellular vesicles (HBMSC-EV) after acute MI.

Methods: FVB mice underwent acute MI via left anterior descending coronary artery ligation and subsequent injection of: (1) IM saline control; (2) IM HBMSC-EV; (3) IV saline control; and (4) IV HBMSC-EV. Cardiac function was evaluated with weekly postoperative echocardiography. On postoperative day 28, the mice were euthanized, and the heart, lungs, liver, spleen, and kidneys were harvested. Given previous studies showing HBMSC-EV hepatic uptake after IV injection, the liver was evaluated for changes in inflammation, fibrosis, and proliferation.

Results: On postoperative day 28, there were no significant differences in left ventricular ejection fraction (P = 0.6151), fractional shortening (P = 0.1135), or anterior border zone fibrosis (P = 0.6333) in any of the experimental groups. Interestingly, there was a strong trend demonstrating improvement in infarct size on fibrosis staining, which did not reach significance (P = 0.05620). There were no differences in hepatic inflammation, fibrosis, and proliferation.

Conclusions: Although there was a trend in the improvement in infarct size, a single-dose administration of neither IM nor IV injection of HBMSC-EV resulted in significant improvement in post-MI cardiac function. A major limitation of this study is the lack of trials determining the optimal dose of HBMSC-EV needed in this model. However, the current study demonstrates that future studies are required to either optimize administration or bioengineer HBMSC-EV with cardiac-homing properties.

Keywords

Human bone mesenchymal stem cell-derived extracellular vesicles / biodistribution / intramyocardial injection / intravenous injection / myocardial infarction

References

[1] Xuan L,Zhen D.Extracellular vesicles derived from human bone marrow mesenchymal stem cells protect rats against acute myocardial infarction-induced heart failure.Cell Tissue Res2022;389:23-40

[2] Potz BA,Pavlov VI,Abid MR.Extracellular vesicle injection improves myocardial function and increases angiogenesis in a swine model of chronic ischemia.J Am Heart Assoc2018;7:e008344 PMCID:PMC6220556

[3] Charles CJ,Yeung T.Systemic mesenchymal stem cell-derived exosomes reduce myocardial infarct size: characterization with MRI in a porcine model.Front Cardiovasc Med2020;7:601990 PMCID:PMC7701257

[4] Gallet R,Valle J.Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction.Eur Heart J2017;38:201-11 PMCID:PMC5837390

[5] Scrimgeour LA,Aboul Gheit A.Extracellular vesicles promote arteriogenesis in chronically ischemic myocardium in the setting of metabolic syndrome.J Am Heart Assoc2019;8:e012617 PMCID:PMC6761642

[6] Scrimgeour LA,Aboul Gheit A.Intravenous injection of extracellular vesicles to treat chronic myocardial ischemia.PLoS One2020;15:e0238879 PMCID:PMC7485873

[7] Xu CM,Brinck-Teixeira R,Sellke FW.Visualization of cardiac uptake of bone marrow mesenchymal stem cell-derived extracellular vesicles after intramyocardial or intravenous injection in murine myocardial infarction.Physiol Rep2023;11:e15568 PMCID:PMC10040402

[8] Kang M,Blenkiron C.Biodistribution of extracellular vesicles following administration into animals: a systematic review.J Extracell Vesicles2021;10:e12085 PMCID:PMC8224174

[9] Wang C,Wu R.Mesenchymal stem cell-derived exosomes and non-coding RNAs: regulatory and therapeutic role in liver diseases.Biomed Pharmacother2023;157:114040

[10] Xu CM,Brinck Teixeira R.Proteomic assessment of hypoxia-pre-conditioned human bone marrow mesenchymal stem cell-derived extracellular vesicles demonstrates promise in the treatment of cardiovascular disease.Int J Mol Sci2023;24:1674 PMCID:PMC9866304

[11] Théry C,Aikawa E.Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines.J Extracell Vesicles2018;7:1535750 PMCID:PMC6322352

[12] Reichert K,McCormack I,Pavlov V.Murine left anterior descending (LAD) coronary artery ligation: an improved and simplified model for myocardial infarction.J Vis Exp2017;122:55353 PMCID:PMC5564466

[13] Li H,Liu W.Plasma exosomes from patients with acute myocardial infarction alleviate myocardial injury by inhibiting ferroptosis through miR-26b-5p/SLC7A11 axis.Life Sci2023;322:121649

[14] Wen S,Papa E.Biodistribution of mesenchymal stem cell-derived extracellular vesicles in a radiation injury bone marrow murine model.Int J Mol Sci2019;20:5468 PMCID:PMC6861905